+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
S

Actively Recruiting

Researchers are studying the safety and effectiveness of two combination treatments for women with HER2-positive metastatic or recurrent breast cancer. This trial focuses on first-line treatments using Inetetamab combined either with Pertuzumab or with Pyrotinib plus chemotherapy. The goal is to find better clinical benefits and offer new targeted treatment options for this condition. Participants receive Inetetamab intravenously every three weeks with a loading dose followed by maintenance doses. One group also receives Pertuzumab intravenously every three weeks, while the other group takes Pyrotinib orally daily. Chemotherapy is chosen by the doctor. Treatments continue until disease progression, unacceptable side effects, or study end. The study is randomized and open-label, comparing these two regimens. During the study, participants will have tumor assessments every six weeks to measure overall response and progression-free survival, lasting up to two years. Safety is monitored through adverse event reporting and heart function tests. The trial also tracks overall survival for up to about 48 months. Participants will be followed closely with clinical evaluations, imaging, and laboratory tests throughout their involvement.

Age: 18Years - 70YearsFEMALEPhase 4
1 location